Effectiveness and Safety of Tirofiban for patients with acute ischemic stroke：A Meta-analysis
- VernacularTitle: 替罗非班治疗急性缺血性卒中安全性及有效性的Meta分析
- Author:
lijun ZHANG
1
;
Xin HU
1
;
Ji LIU
1
Author Information
- Publication Type:Journal Article
- Keywords: Antiplatelet; Tirofiban; Acute ischemic stroke; Safety; Effectiveness; Meta analysis
- From: Journal of Apoplexy and Nervous Diseases 2020;37(7):594-599
- CountryChina
- Language:Chinese
- Abstract: Objective To systematically evaluate the efficacy and safety of tirofiban for patients with acute ischemic stroke. Methods Three electronic information sources （PubMed、EMBASE、Cochrane Library） were searched to identify relevant clinical studies on tirofiban in the treatment of people with acute ischemic stroke from initiation of the databases to August 31，2019.The reviewers extracted the data and assessed the quality of included studies，then meta-analysis is performed by RevMan 5.3 software. Results We included twelve trials involving 2137 participants. The trial group had 921 patients，the control group had 1216 patients. The patients in trial group had lower NHISS scorce at 2～7 days after the therapy of tirofiban ［Mean Difference（MD）=-1.53，95% Confidence Interval（CI） -2.98～-0.09，P=0.04］.The use of tirofiban could increase the proportion of 90-day favorite outcome of AIS patients significantly，but did not improve the condition of recanalization of the blood vessels in 24 hours after the therapy of tirofiban. At the same time，tirofiban significantly reduced the 90-day mortality （RR=0.79，95%CI 0.65～0.97，P=0.02），and did not increase the intracranial hemorrhage rate （intracranial hemorraghic transformation：RR=0.89，95%CI 0.77～1.03，P=0.11；symptomatic intracranial hemorrhage：RR=0.93，95%CI 0.70～1.25，P=0.64）. Conclusion Tirofiban administration is safe in patients with AIS，and can significantly improve the symptoms of early neurological impairment，a good prognosis at 90 days，and can reduce the risk of death at 90 days. But it does not improve the vascular recanalization within 24 hours treatment.
- Full text:2024080121503721366替罗非班治疗急性缺血性卒中安全性及有效性的Meta分析.pdf
